Roche Pact Is Affirmation Of Affimed Technology
Beware the hype but a deal with one of the big oncology players that involves $96m upfront and potentially $5.0bn in milestones is a decent validation for the German biotech's technology platform.
You may also be interested in...
Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.
German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.
Biopharma financing reached $14.6 billion in the third quarter, a 15% increase over Q2, while merger and acquisitions, at $7.7 billion (the lowest quarter of the year so far), showed a sharp decline. Alliance value reached $20.3 billion, far exceeding the $13.8 billion from Q2.